Qlife Holding AB (publ) (QLIFE.ST)
SEK 2.1
(5.53%)
SEK 2.1
(5.53%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -150.5 Million SEK | 43.64% |
| 2022 | -78.04 Million SEK | -120.11% |
| 2021 | -35.12 Million SEK | -82.57% |
| 2020 | -19.48 Million SEK | -514.76% |
| 2019 | -3.23 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -8 Million SEK | 31.7% |
| 2024 Q1 | -11.71 Million SEK | -23.78% |
| 2023 FY | - SEK | 43.64% |
| 2023 Q3 | -6.66 Million SEK | 59.1% |
| 2023 Q4 | -9.46 Million SEK | -42.1% |
| 2023 Q1 | -11.57 Million SEK | 55.96% |
| 2023 Q2 | -16.28 Million SEK | -40.74% |
| 2022 Q3 | -14.85 Million SEK | 27.99% |
| 2022 Q2 | -20.62 Million SEK | -26.55% |
| 2022 Q1 | -16.29 Million SEK | -36.65% |
| 2022 FY | - SEK | -120.11% |
| 2022 Q4 | -26.28 Million SEK | -76.97% |
| 2021 Q1 | -3.19 Million SEK | 50.82% |
| 2021 FY | - SEK | -82.57% |
| 2021 Q4 | -11.92 Million SEK | 2.48% |
| 2021 Q3 | -12.22 Million SEK | -76.27% |
| 2021 Q2 | -6.93 Million SEK | -116.98% |
| 2020 FY | - SEK | -514.76% |
| 2020 Q4 | -6.5 Million SEK | -28.94% |
| 2020 Q3 | -5.04 Million SEK | -159.1% |
| 2020 Q2 | -1.94 Million SEK | 66.05% |
| 2020 Q1 | -5.73 Million SEK | 51.92% |
| 2019 Q3 | -2.43 Million SEK | 4.99% |
| 2019 FY | - SEK | 0.0% |
| 2019 Q1 | -1.87 Million SEK | 0.0% |
| 2019 Q2 | -2.56 Million SEK | -36.75% |
| 2019 Q4 | -11.92 Million SEK | -389.45% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acarix AB (publ) | -77.12 Million SEK | -95.152% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 136.539% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 136.539% |
| Arcoma AB | 6.24 Million SEK | 2508.851% |
| Bactiguard Holding AB (publ) | -89.98 Million SEK | -67.261% |
| BICO Group AB (publ) | 322.3 Million SEK | 146.697% |
| Boule Diagnostics AB (publ) | 65.97 Million SEK | 328.11% |
| CellaVision AB (publ) | 207.24 Million SEK | 172.622% |
| Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | -120.017% |
| Chordate Medical Holding AB (publ) | -27.94 Million SEK | -438.614% |
| C-Rad AB (publ) | 48.9 Million SEK | 407.756% |
| Duearity AB (publ) | -24.77 Million SEK | -507.389% |
| Dignitana AB (publ) | -264 Thousand SEK | -56909.47% |
| Episurf Medical AB (publ) | -87.7 Million SEK | -71.613% |
| Getinge AB (publ) | 5.92 Billion SEK | 102.538% |
| Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | -123.799% |
| Iconovo AB (publ) | -35.33 Million SEK | -325.932% |
| Integrum AB (publ) | 8.76 Million SEK | 1817.794% |
| Luxbright AB (publ) | -23.86 Million SEK | -530.606% |
| Mentice AB (publ) | 28.87 Million SEK | 621.266% |
| OssDsign AB (publ) | -122.02 Million SEK | -23.344% |
| Paxman AB (publ) | 31.22 Million SEK | 581.94% |
| Promimic AB (publ) | -3.68 Million SEK | -3985.37% |
| SciBase Holding AB (publ) | -51.82 Million SEK | -190.388% |
| ScandiDos AB (publ) | -13.35 Million SEK | -1026.872% |
| Sectra AB (publ) | 615.06 Million SEK | 124.47% |
| Sedana Medical AB (publ) | -51.67 Million SEK | -191.259% |
| Senzime AB (publ) | -118.82 Million SEK | -26.663% |
| SpectraCure AB (publ) | -20.96 Million SEK | -617.75% |
| Stille AB | 56.04 Million SEK | 368.562% |
| Vitrolife AB (publ) | -3.18 Billion SEK | 95.275% |
| Xvivo Perfusion AB (publ) | 126.57 Million SEK | 218.907% |